Hologic and R2 sign definitive agreement
A deal announced July 31 between women's health equipment vendor Hologic and R2 Technology calls for the integration of the CAD pioneer's ImageChecker into Hologic's Lorad Selenia full-field digital mammography system. The agreement grants Hologic
A deal announced July 31 between women's health equipment vendor Hologic and R2 Technology calls for the integration of the CAD pioneer's ImageChecker into Hologic's Lorad Selenia full-field digital mammography system. The agreement grants Hologic worldwide distribution rights for R2's OmniCAD Digital and film-based mammography suite of products customized for use with Selenia. The five-year agreement, which has two one-year renewal options, also provides Hologic the right to sell R2's film-based CAD products in conjunction with its digital-ready conventional screen-film mammography products.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
